ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Potential anti-glioma targets and mechanisms of Smilax china L. based on network pharmacological, molecular docking and experimental verification.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Glioma, the most common primary malignant brain tumor, urgently requires effective treatments. Traditional Chinese herbal medicine, with its multi-target and low side effects, shows potential in anti-tumor treatment. Smilax china L. (SCL) resists various tumors, but its effect on gliomas is unknown. This study evaluated the impact and mechanism of SCL on glioma. Results showed intragastric administration of 0.5 and 1.5 g/kg SCL significantly inhibited glioma growth and prolonged survival in tumor-bearing mice. Bioinformatics analysis identified 84 intersection targets SCL and glioma. GO and KEGG analyses suggested that the EGFR/Akt/mTOR and EGFR/STAT3 pathways play important roles. Molecular docking highlighted Diosgenin and Pseudodiosgenin as key active compounds with strong binding ability to screened targets. In vitro verification confirmed these compounds inhibited glioma cell proliferation and induced apoptosis. Western blot analysis confirmed that SCL inhibits glioma via the EGFR/Akt/mTOR and EGFR/STAT3 pathways. Collectively, our findings comprehensively elucidated the active compounds, potential targets, and molecular mechanisms of SCL against glioma, providing a promising strategy for the scientific basis and therapeutic mechanism of traditional Chinese medicine prescriptions for the treatment of the disease.
Indexed as
Identifiers
41792454What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.